MARKET

SESN

SESN

Sesen Bio, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.540
+0.200
+8.55%
After Hours: 2.585 +0.045 +1.77% 17:46 05/17 EDT
OPEN
2.340
PREV CLOSE
2.340
HIGH
2.555
LOW
2.320
VOLUME
2.86M
TURNOVER
--
52 WEEK HIGH
3.570
52 WEEK LOW
0.6620
MARKET CAP
440.15M
P/E (TTM)
-14.5392
1D
5D
1M
3M
1Y
5Y
Trv Gp, Llc Buys Sesen Bio Inc
GuruFocus News · 5d ago
Sesen Bio Files Shelf for Up to $200 Million in Securities
MT Newswires · 6d ago
BRIEF-Sesen Bio Files For Mixed Shelf Of Up To $200 Mln
reuters.com · 05/10 13:30
Sesen Bio Reports First Quarter 2021 Financial Results and Commercial Launch Readiness Update in the US for Vicineum
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the first quarter ended March 31, 2021. The Company’s Biologics License ...
Business Wire · 05/10 12:30
Sesen Bio shares fall after Q1 net loss
Sesen Bio (SESN) shares fall more than 3% during premarket trading after the company posted a net loss in the first quarter of 2021.Net loss was $55.5M, or $0.35 per share, in
Seekingalpha · 05/10 12:29
Sesen Bio Q1 EPS $(0.35) Misses $(0.08) Estimate
Sesen Bio (NASDAQ:SESN) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.08) by 337.5 percent. This is a 212.9 percent decrease over earnings of $0.31 per share from the
Benzinga · 05/10 11:42
Sesen Bio EPS misses by $0.27
Sesen Bio (SESN): Q1 GAAP EPS of -$0.35 misses by $0.27.Cash, cash equivalents and restricted cash of $110M.Shares are down 1.12% PM.Press Release
Seekingalpha · 05/10 11:34
10-Q: SESEN BIO, INC.
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. The following discussion and...
Edgar Online - (EDG = 10Q, 10K) · 05/10 11:33
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SESN. Analyze the recent business situations of Sesen Bio, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SESN stock price target is 7.00 with a high estimate of 8.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 88
Institutional Holdings: 41.76M
% Owned: 24.10%
Shares Outstanding: 173.29M
TypeInstitutionsShares
Increased
19
5.20M
New
16
697.63K
Decreased
8
1.15M
Sold Out
2
1.56M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Independent Director
Jay Duker
President/Chief Executive Officer/Director
Thomas Cannell
Chief Financial Officer/Treasurer
Monica Forbes
Chief Technology Officer
Glen MacDonald
Chief Accounting Officer/Controller
Elly Ryu
General Counsel/Secretary
Mark Sullivan
Independent Director
Carrie Bourdow
Independent Director
Jane Henderson
Independent Director
Jason Keyes
Independent Director
Daniel Lynch
No Data
About SESN
Sesen Bio, Inc., formerly Eleven Biotherapeutics, Inc., is a late-stage clinical company that provides targeted protein therapeutics (TPT) platform. The Company is focused on developing antibody-drug conjugate (ADC) therapies for the treatment of cancer. Its product pipeline includes Vicinium, Vicinium in combination with checkpoint inhibator, durvalumab, and VB6-845d. The Company’s lead program, Vicinium, is a fusion protein in Phase III development for the treatment of non-muscle invasive bladder cancer (NMIBC). It targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent cytotoxin, Pseudomonas Exotoxin A (ETA) directly to cancer cells.

Webull offers kinds of Sesen Bio Inc stock information, including NASDAQ:SESN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SESN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SESN stock methods without spending real money on the virtual paper trading platform.